List view / Grid view
Lilly has announced new findings from separate studies of Trulicity (dulaglutide) and…
Lilly has announced new findings from separate studies of Trulicity (dulaglutide) and Tradjenta (linagliptin) at the American Diabetes Association 76th Scientific Sessions.
Boehringer Ingelheim and Eli Lilly and Company announced today the…
19 March 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company announced today the initiation of a Phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albuminuria, and urinary albumin-to-creatinine (UACR) ratio 30-3000 mg/g creatinine, in addition to current standard therapy for diabetic nephropathy.…
The European Commission has approved Galvus® (vildagliptin) (50 mg once…
5 December 2011 | By Novartis
The European Commission has approved Galvus® (vildagliptin) (50 mg once a day) for the treatment of type 2 diabetes patients with moderate or severe renal impairment...
